Loading...
Market
How many units of Eli Lilly's Zepbound vials will be sold in the U.S. by March 31, 2025?
2
Resolution / Starting Odds
Less than 500,000 units • 25%
500,000 to 1 million units • 25%
1 million to 2 million units • 25%
More than 2 million units • 25%
Sales reports from Eli Lilly, market research firms, or major news outlets
Story
Eli Lilly Releases Tirzepatide Vials at 50% Discount to Boost Access and Supply
Aug 26, 2024, 03:00 PM
Eli Lilly has announced the release of single-dose vials of its popular weight-loss drug, Zepbound (tirzepatide), in the U.S. The vials are available in 2.5 mg and 5 mg doses, priced at $399 and $549 per month, respectively. This move aims to expand supply and accessibility, particularly for patients who cannot get the cost of the medicine reimbursed through their health insurance plans. The introduction of these vials is expected to ease supply constraints and provide a more affordable option compared to injection pens, which are priced higher.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
5 or more new partnerships • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%